Drug Overview

Darovasertib is an experimental “smart” targeted cancer drug designed to treat certain rare eye cancers. It is not a traditional chemotherapy that attacks all fast-growing cells. Instead, it is a precision therapy that blocks a specific protein called protein kinase C (PKC), which is overactive in tumors with certain genetic changes.

Darovasertib is taken by mouth as tablets and is being studied mainly for uveal melanoma, a type of eye cancer that often spreads to the liver. Because it is still investigational, it is used only in clinical trials, often combined with another targeted drug called crizotinib. Its goal is to slow tumor growth in patients who have few other good treatment options.

Generic Name: Darovasertib (also known as IDE196 or NVP-LXS196).
US Brand Names: None; darovasertib is an investigational agent and is not marketed under a commercial brand name.
Drug Class: Protein kinase C (PKC) inhibitor / Targeted therapy.
Route of Administration: Oral tablets, taken by mouth.
FDA Approval Status: Investigational; not currently approved by the U.S. Food and Drug Administration for standard clinical use. Has orphan drug designation for uveal melanoma. Being studied in phase 3 clinical trials, mainly for metastatic uveal melanoma.

What Is It and How Does It Work? (Mechanism of Action)

Darovasertib works as a “smart” targeted therapy by blocking protein kinase C (PKC), a key enzyme in cancer signaling pathways. About 90% of uveal melanomas have mutations in GNAQ or GNA11 genes. These mutations keep PKC turned on all the time, sending constant “grow and survive” signals to cancer cells.

At the molecular level, darovasertib binds to the ATP pocket of several PKC isoforms, especially PKCα and PKCβ. This stops PKC from adding phosphate groups to its target proteins. One key target is MARCKS, a protein that helps cancer cells move and survive. Blocking PKC also shuts down the downstream MAPK/ERK pathway, which controls cell growth and division. Within hours of taking the drug, levels of phosphorylated ERK drop, slowing tumor growth.

The drug may also make cancer cells more sensitive to cell death by disrupting other survival signals. Because it targets the exact mutation-driven pathway in uveal melanoma, darovasertib can shrink tumors or slow their spread, especially when combined with MEK inhibitors that hit the same pathway further downstream. This makes it a precision medicine for genetically defined cancers.

FDA Approved Clinical Indications

Darovasertib does not currently have any FDA-approved indications for routine clinical use. It has orphan drug status for uveal melanoma, recognizing its potential for this rare cancer.

Oncological uses (in clinical trials)

Metastatic uveal melanoma (MUM), especially when first-line treatment for tumors with GNAQ or GNA11 mutations, often combined with crizotinib.
Primary uveal melanoma, in neoadjuvant or adjuvant settings to shrink tumors before surgery or prevent spread after treatment.
Other solid tumors harboring GNAQ/GNA11 mutations or PKC fusions, such as certain colorectal cancers or cutaneous melanomas (early exploratory studies).

Because darovasertib is still experimental, it is only available through approved clinical trials at specialized medical centers.

Non-oncological uses (if any)

There are currently no FDA-approved non-cancer (non-oncological) uses for darovasertib. Its development focuses entirely on oncology, particularly mutation-driven eye cancers.

Dosage and Administration Protocols

Darovasertib is taken as oral tablets, usually twice daily. Because it is investigational, exact doses vary by trial, but phase 2/3 studies use a standard expansion dose. It is often combined with crizotinib, requiring careful timing.

Feature	Description
Standard dose (investigational)	300 mg taken orally twice daily (recommended phase 2 dose).
Frequency of administration	Twice daily, at consistent times, continuously in cycles.
Route of administration	Oral tablets, swallowed whole with water; may be taken with or without food.
Typical treatment duration	Continues in cycles (e.g., 28 days on, with scans every 6-8 weeks) as long as the cancer responds and side effects are manageable.
Dose adjustments (renal/hepatic insufficiency)	No routine adjustments needed for mild-moderate kidney or liver issues. Use caution in severe cases; dose may be reduced or paused based on blood tests and toxicity. In combination trials, adjust both drugs if needed.

Patients must follow trial protocols exactly. Missed doses should be taken as soon as remembered unless close to the next dose.

Clinical Efficacy and Research Results

Darovasertib has shown promising early results in trials from 2020-2025, mainly in metastatic uveal melanoma patients with GNAQ/GNA11 mutations. Phase 1/2 studies (like NCT03947385) reported disease control in over half of heavily pretreated patients, with some partial responses and stable disease lasting months.

When combined with crizotinib, response rates improved significantly. In expansion cohorts, the combo showed tumor shrinkage in many patients with liver metastases, a hard-to-treat group. Phase 2/3 trials ongoing since 2023 report progression-free survival benefits over standard care, though exact median survival numbers await full reporting. Pharmacodynamic data confirm rapid PKC inhibition and ERK suppression, linking drug levels to tumor response.

Real-world and neoadjuvant studies also suggest darovasertib reduces tumor size before surgery in primary uveal melanoma. While large survival data from 2020-2025 are still maturing, early signals support its role in this orphan cancer with limited options.

Safety Profile and Side Effects

Darovasertib is generally tolerable as an oral targeted therapy, with a profile better than earlier PKC inhibitors. No Black Box Warning exists, as it is investigational.

Common side effects (>10%)

Skin rash or dryness.
Fatigue or feeling tired.
Nausea or poor appetite.
Diarrhea.
Headache.
Muscle or joint pain.

These are often mild and managed with supportive care like moisturizers, anti-nausea drugs, or rest.

Serious adverse events

Severe skin reactions (rash, inflammation).
Liver enzyme elevations or hepatitis.
Vision changes or eye irritation (due to eye cancer focus).
Gastrointestinal perforation (rare, with MEK combos).
Heart rhythm changes or inflammation.

Management strategies

For rash, use steroid creams and avoid sun; pause drug if severe.
Monitor liver tests every 2 weeks initially; hold dose if levels rise sharply.
Eye exams before and during treatment for uveal melanoma patients.
Hydrate for diarrhea; use anti-diarrheals if needed.
Report chest pain, vision loss, severe abdominal pain, or worsening rash immediately.

Connection to Stem Cell and Regenerative Medicine

No direct evidence links darovasertib to stem cell transplantation or regenerative medicine. Its role is as a targeted PKC inhibitor for mutation-driven solid tumors.

Research areas include combinations with immunotherapy. Trials test darovasertib plus checkpoint inhibitors to boost T-cell activity in “cold” tumors like uveal melanoma. PKC inhibition may reprogram the tumor microenvironment, making it more responsive to PD-1 blockers. Early combo data suggest improved infiltration of immune cells.

Patient Management and Practical Recommendations

Darovasertib requires genetic testing and close monitoring in trials.

Pre-treatment tests to be performed

Genetic testing: Confirm GNAQ/GNA11 mutations in tumor tissue.
Blood tests: Liver/kidney function, blood counts.
Eye exam: Baseline ophthalmology evaluation.
Imaging: CT/MRI/PET to measure tumors, especially liver metastases.
Heart tests: ECG if cardiac risks exist.

Precautions during treatment

Protect skin from sun; use sunscreen and cover up.
Report eye changes, vision blur, or flashes immediately.
Avoid grapefruit or strong CYP3A drugs that affect drug levels.
Attend frequent scans and bloodwork per trial schedule.

“Do’s and Don’ts” list

DO take darovasertib twice daily at set times.
DO moisturize skin and use gentle soap.
DO get eye checks and liver tests as scheduled.
DO report new rashes, diarrhea, or fatigue promptly.
DON’T miss doses or change timing without trial team advice.
DON’T take herbal supplements or new meds without approval.
DON’T ignore vision changes or severe GI symptoms.
DON’T stop treatment assuming improvement means cure.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice or a treatment recommendation. Darovasertib is an investigational targeted therapy not approved by the U.S. Food and Drug Administration (FDA) for routine use. It is available only through clinical trials. Individual responses vary, and outcomes cannot be guaranteed. Patients should consult a qualified oncologist for diagnosis, treatment options, and trial eligibility. The hospital and its staff are not responsible for decisions based on this information.